Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

pembrolizumab 67Cyclophosphamide 45Cisplatin 45Nivolumab 39Paclitaxel 35Carboplatin 31Radiotherapy 30Gemcitabine 28Docetaxel 27Dexamethasone 23atezolizumab 22Bevacizumab 20Doxorubicin 19Vincristine 17Magnetic Resonance Spectroscopy 17Lenalidomide 17fludarabine 16Radiosurgery 16Fluorouracil 16Etoposide 16Blood Specimen Collection 16Rituximab 15Radiation 15Letrozole 15Irinotecan 15Ipilimumab 15palbociclib 14Leucovorin 14Cytarabine 14Surveys and Questionnaires 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urate Oxidase × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡